A(2A) blockade enhances anti-metastatic immune responses

The specific targeting of tumor-elicited immunosuppression is a promising strategy for the treatment of cancer. We have recently demonstrated that targeting the immunosuppressive pathway mediated by CD73-derived adenosine through the blockade of A(2A)/A(2B) adenosine receptors significantly reduced...

Descripción completa

Detalles Bibliográficos
Autores principales: Beavis, Paul A, Milenkovski, Nicole, Stagg, John, Smyth, Mark J, Darcy, Phillip K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926871/
https://www.ncbi.nlm.nih.gov/pubmed/24575377
http://dx.doi.org/10.4161/onci.26705
_version_ 1782304032181714944
author Beavis, Paul A
Milenkovski, Nicole
Stagg, John
Smyth, Mark J
Darcy, Phillip K
author_facet Beavis, Paul A
Milenkovski, Nicole
Stagg, John
Smyth, Mark J
Darcy, Phillip K
author_sort Beavis, Paul A
collection PubMed
description The specific targeting of tumor-elicited immunosuppression is a promising strategy for the treatment of cancer. We have recently demonstrated that targeting the immunosuppressive pathway mediated by CD73-derived adenosine through the blockade of A(2A)/A(2B) adenosine receptors significantly reduced the metastatic potential of CD73(+) breast carcinomas and melanomas via both immunological and non-immunological mechanisms.
format Online
Article
Text
id pubmed-3926871
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-39268712014-02-26 A(2A) blockade enhances anti-metastatic immune responses Beavis, Paul A Milenkovski, Nicole Stagg, John Smyth, Mark J Darcy, Phillip K Oncoimmunology Author's View The specific targeting of tumor-elicited immunosuppression is a promising strategy for the treatment of cancer. We have recently demonstrated that targeting the immunosuppressive pathway mediated by CD73-derived adenosine through the blockade of A(2A)/A(2B) adenosine receptors significantly reduced the metastatic potential of CD73(+) breast carcinomas and melanomas via both immunological and non-immunological mechanisms. Landes Bioscience 2013-12-01 2013-10-22 /pmc/articles/PMC3926871/ /pubmed/24575377 http://dx.doi.org/10.4161/onci.26705 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Beavis, Paul A
Milenkovski, Nicole
Stagg, John
Smyth, Mark J
Darcy, Phillip K
A(2A) blockade enhances anti-metastatic immune responses
title A(2A) blockade enhances anti-metastatic immune responses
title_full A(2A) blockade enhances anti-metastatic immune responses
title_fullStr A(2A) blockade enhances anti-metastatic immune responses
title_full_unstemmed A(2A) blockade enhances anti-metastatic immune responses
title_short A(2A) blockade enhances anti-metastatic immune responses
title_sort a(2a) blockade enhances anti-metastatic immune responses
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926871/
https://www.ncbi.nlm.nih.gov/pubmed/24575377
http://dx.doi.org/10.4161/onci.26705
work_keys_str_mv AT beavispaula a2ablockadeenhancesantimetastaticimmuneresponses
AT milenkovskinicole a2ablockadeenhancesantimetastaticimmuneresponses
AT staggjohn a2ablockadeenhancesantimetastaticimmuneresponses
AT smythmarkj a2ablockadeenhancesantimetastaticimmuneresponses
AT darcyphillipk a2ablockadeenhancesantimetastaticimmuneresponses

Ejemplares similares